ISRIBの結合は,ニュクレオチド交換因子eIF2Bの規制部位を明らかにする.
PubMedで要約を見る
まとめ
この要約は機械生成です。統合ストレス反応 (ISR) 阻害剤ISRIBはeIF2B複合体と結合し,重要な調節部位を明らかにする. この構造的な洞察は,ISRIBが翻訳をどのように調節し,神経変性疾患の潜在的な治療目標を提供することを説明します.
科学分野
- 分子生物学
- 構造生物学
- 神経科学
背景
- 統合ストレス反応 (ISR) は,細胞の伝達,代謝,記憶,免疫を調節する重要な経路です.
- ストレス誘発によるユカリオット翻訳開始因子2α (eIF2α) のリン酸化は,ISRの重要なステップであるグアニン核酸交換因子eIF2Bを阻害する.
- 化学的ISR阻害剤であるISRIBは,神経変性や脳外傷のモデルにおいて神経保護効果を示している.
研究 の 目的
- ISRIBがISRを阻害する分子メカニズムを解明する.
- ISRIBとeIF2Bコンプレックスとの相互作用の構造的基盤を決定する.
- ISRを調節するための潜在的な治療標的を特定する.
主な方法
- クリオ電子顕微鏡 (cryo-EM) で,人間のeIF2BがISRIBに結合する構造を4. 1アングストームの解像度で決定する.
- ISRIB結合ポケット内の残留物の役割を調査するサイト指向型変異.
- ISRIB活性に対する変異の機能的影響を評価するために,in vitroおよびin vivoの測定を行う.
主要な成果
- 凍結-EM構造は,eIF2B βおよびδサブユニットのインターフェイスでISRIBが結合することを明らかにしました.
- ISRIBの結合ポケットを覆う残留物の変異は,ISRIBの結合と細胞応答にとって重要であることが示された.
- 特定された結合部位は,eIF2BのeIF2α媒介による衰弱を逆転させるISRIBの能力を分子的に説明する.
結論
- この研究は,eIF2B複合体内のISRIBの特定の結合部位を明らかにし,その作用機構を明らかにした.
- このISRIB-eIF2Bの相互作用の構造的および機能的特徴は,ISRを標的とした新しい治療法を開発するための道を開きます.
- この発見は,様々な病気の文脈で翻訳を規制するためにこのサイトを活用する可能性を強調しています.
関連する概念動画
Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome. Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...

